Sign in

RGC on Nasdaq

Regencell Bioscience

Logo: regencellbioscience.com3

Traditional Chinese herbal treatment company founded in 20141

In its 2026 annual report (Form 20-F) the company says: “We, Regencell Bioscience Holdings Limited, are a holding company incorporated as an exempted company on October 30, 2014, under the laws of the Cayman Islands, which has no substantive operations other than holding all of the issued and outstanding shares of Regencell Bioscience Limited, Regencell Limited and Regencell Bioscience North America Limited.”6 It is headquartered in Hong Kong.1 Its shares trade on Nasdaq under the symbol RGC.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$11.7MNet income, fiscal 20264
2014Founded1

Compare with another stock.

  • TickerRGC on Nasdaq1
  • IndustryMedicinal Chemicals & Botanical Products1
  • HeadquartersHong Kong1
  • Websiteregencellbioscience.com
  • Incorporated inCayman Islands5
  • Business address9/F Chinachem Leighton Plaza, 29 Leighton Road, Causeway Bay, Hong Kong5
  • Filer categoryLarge accelerated filer5

See how the biggest companies compare on our leaderboards

We, Regencell Bioscience Holdings Limited, are a holding company incorporated as an exempted company on October 30, 2014, under the laws of the Cayman Islands, which has no substantive operations other than holding all of the issued and outstanding shares of Regencell Bioscience Limited, Regencell Limited and Regencell Bioscience North America Limited. Our principal executive offices are located at 9/F Chinachem Leighton Plaza, 29 Leighton Road, Causeway Bay, Hong Kong. Our telephone number at this address is +852 2155-0823. Our registered office in the Cayman Islands is at the offices of Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands. Our corporate website is https://www.regencellbioscience.com. The SEC maintains a website at www.sec.gov that contains reports, proxy statements and other information regarding us that file electronically wi…6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-87.7%Return on equity4

Financial statements

Operating income78910114-$11.7M in 2026+2899% since 2019
-$15.0M-$10.0M-$5.0M02019: -$391.0K-$391.0K20192020: -$812.4K-$812.4K2020+108%2021: -$1.4M-$1.4M2021+70%2022: -$7.6M-$7.6M2022+451%2023: -$6.3M-$6.3M2023−18%2024: -$4.7M-$4.7M2024−24%2025: -$3.8M-$3.8M2025−20%2026: -$11.7M-$11.7M2026+211%
Net income7910114-$11.7M in 2026+2893% since 2019
-$15.0M-$10.0M-$5.0M02019: -$391.0K-$391.0K20192020: -$812.4K-$812.4K2020+108%2021: -$1.3M-$1.3M2021+66%2022: -$7.4M-$7.4M2022+453%2023: -$5.9M-$5.9M2023−21%2024: -$4.3M-$4.3M2024−27%2025: -$3.6M-$3.6M2025−17%2026: -$11.7M-$11.7M2026+226%

Every line of the income statement as filed: the last 3 fiscal years, latest first.11

Period ending2025-06-302024-06-302023-06-30
Selling and marketing$8.0K$125.4K$262.7K
General and administrative (including share-based compensation of $0.20 million, $0.48 million and $0.89 million for the years ended June 30, 2025, 2024 and 2023 respectively)$2.8M$3.5M$4.4M
Research and development (including share-based compensation of $0.04 million, reversal of share-based compensation of $0.03 million and share-based compensation of $0.03 million for the years ended June 30, 2025, 2024 and 2023 respectively)$948.3K$1.1M$1.6M
Total operating expenses$3.8M$4.7M$6.3M
LOSS FROM OPERATIONS-$3.8M-$4.7M-$6.3M
OTHER INCOME, NET$185.8K$373.5K$211.3K
LOSS BEFORE INCOME TAXES-$3.6M-$4.4M-$6.1M
NET LOSS-$3.6M-$4.4M-$6.1M
Shareholders of the Company-$3.6M-$4.3M-$5.9M
Non-controlling interest-$61.4K-$191.2K
Foreign currency translation adjustment-$19.0K$40.9K-$86.7K
Shareholders of the Company-$3.6M-$4.3M-$6.0M
Non-controlling interest-$61.4K-$191.2K
TOTAL NET COMPREHENSIVE LOSS-$3.6M-$4.3M-$6.1M
Basic (in Shares)494.5M shares494.5M shares494.5M shares
Diluted (in Shares)494.5M shares494.5M shares494.5M shares
Basic (in Dollars per share)-$0.72-$0.87-$1.19
Diluted (in Dollars per share)-$0.72-$0.87-$1.19

Compare Regencell Bioscience with another company

Corporate structure

Regencell Bioscience sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Regencell Bioscience

  • Regencell Bioscience Hong Kong

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Regencell Bioscience reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.1M4 Jun 30, 2026$1.1M4 Jun 30, 2025+0.1%
Accumulated depreciation$939.0K4 Jun 30, 2026$857.3K4 Jun 30, 2025+9.5%
Property and equipment, net$135.1K4 Jun 30, 2026$215.4K4 Jun 30, 2025−37.3%
Operating-lease assets (leased space)$295.6K4 Jun 30, 2026$544.4K4 Jun 30, 2025−45.7%

Investments

ItemLatestA year beforeChange
Marketable securities, current$2.5M4 Jun 30, 2025$5.0M11 Jun 30, 2024−50.4%

Leadership

Who has led Regencell Bioscience, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Yat-Gai Au2026–now
201520202025
Board members and other officers (6)

Timeline

  1. Mar 18, 2026New chief executive Yat-Gai Au becomes CEO12
  2. 2021Went public Listed on NASDAQ1
  3. 2014Founded Founded1

Filings

56 filings to the SEC since October 2021: 6 annual reports, 9 insider forms, 8 large holders, 33 other. The latest 20:

  1. Oct 7, 202620-F ANNUAL REPORT EDGAR
  2. May 29, 20264 EDGAR
  3. May 29, 20264 EDGAR
  4. May 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. May 19, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  6. May 19, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. May 19, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. May 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Apr 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Mar 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  11. Mar 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. Mar 30, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  13. Mar 30, 2026F-3ASR REGISTRATION STATEMENT EDGAR
  14. Mar 18, 20263 EDGAR
  15. Mar 18, 20263 EDGAR
  16. Mar 18, 20263 EDGAR
  17. Mar 18, 20263 EDGAR
  18. Mar 18, 20263 EDGAR
  19. Mar 18, 20263 EDGAR
  20. Mar 18, 20263 EDGAR

The 56 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Regencell Bioscience is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRegencell Bioscience Holdings Ltd2
  • CIK0001829667
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company6
  • Incorporated inCayman Islands6
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address9/F Chinachem Leighton Plaza, 29 Leighton Road, Causeway Bay, Hong Kong, China2
  • Phone852 2155 08232
  • Shares outstanding495,884,376 shares as of Jun 30, 20266
  • AuditorHTL International, LLC, Houston, Texas PCAOB ID 7000; it also attests to the company’s internal control over financial reporting6
  • On EDGAR sinceNov 13, 20202
  • Filings85 in all: 6-K (34), 3 (7), 20-F (6), CORRESP (6), SC 13D/A (5), UPLOAD (5), F-1/A (3), 4 (2)2
    All 22 form types

    424B5 (2), FWP (2), SCHEDULE 13D/A (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), F-1 (1), F-3ASR (1), SC 13D (1), SC 13G (1)

  • Latest filingsAnnual report (20-F) Oct 7, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary shares, par value $0.00001RGCNASDAQ

From the cover page of the 20-F filed Oct 7, 2026 (Section 12(b) of the Exchange Act).6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19